seeing as threadmeister skhammer ("...any specific questions, feel free to post them as Purple, myself and Russell should be able to answer them...") has put me on notice, I should attempt to answer the questions, instead on my usual stream of consciousness waffle (dang - there I go again.)
AHZ surgical patch: yes, there are signs that this could get approved in the near term, but my gut feeling is that this will take longer: I just don't see cardiocel contributing to revenue in the next 12 months.
HPV therapeutic - pre clinical results by end of year - just be aware that this is the dawn of the first day of eternity. These things take years.
HSV, as you mention, approaching phase-1 2013.
See the annual report to shareholders.
The dark horse is the original Allied sales base, of surgical apparatus of which I know nothing. If AHZ's books show steady profit from the old bread and butter, then they will be in the enviable position of being a research & development company with an independent cash-flow.
On the other hand, if that side of the business struggles then it will be a brake on the glittery R&D side.
- Forums
- ASX - By Stock
- biotech thread - wednesday 31st october
seeing as threadmeister skhammer ("...any specific questions,...
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)